Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
|
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
  • [41] Advancing drug delivery systems for the treatment of multiple sclerosis
    Tabansky, Inna
    Messina, Mark D.
    Bangeranye, Catherine
    Goldstein, Jeffrey
    Blitz-Shabbir, Karen M.
    Machado, Suly
    Jeganathan, Venkatesh
    Wright, Paul
    Najjar, Souhel
    Cao, Yonghao
    Sands, Warren
    Keskin, Derin B.
    Stern, Joel N. H.
    IMMUNOLOGIC RESEARCH, 2015, 63 (1-3) : 58 - 69
  • [42] Drug satisfaction in multiple sclerosis using fingolimod treatment
    Terzi, M.
    Evin, O.
    Terzi, Y.
    Sen, S.
    Ecem, A.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 1058 - 1059
  • [43] An Investigation into the Desire for Personalised Information Provision by People with Multiple Sclerosis
    Qutaishat, Fadi T.
    Probets, Steve
    Hepworth, Mark
    BUSINESS TRANSFORMATION THROUGH INNOVATION AND KNOWLEDGE MANAGEMENT: AN ACADEMIC PERSPECTIVE, VOLS 1-2, 2010, : 458 - +
  • [44] PHARMACOGENOMICS AND PERSONALISED MEDICINE FOR DRUGS OF THE CARDIOVASCULAR SYSTEM
    Manolopoulos, V
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 5 - 5
  • [45] Erratum to: Advancing drug delivery systems for the treatment of multiple sclerosis
    Inna Tabansky
    Mark D. Messina
    Catherine Bangeranye
    Jeffrey Goldstein
    Karen M. Blitz-Shabbir
    Suly Machado
    Venkatesh Jeganathan
    Paul Wright
    Souhel Najjar
    Yonghao Cao
    Warren Sands
    Derin B. Keskin
    Joel N. H. Stern
    Immunologic Research, 2016, 64 : 640 - 640
  • [46] Outcomes assessment of drug treatment in multiple sclerosis clinical trials
    Malone, M
    Lomaestro, B
    PHARMACOECONOMICS, 1996, 9 (03) : 198 - 210
  • [47] New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimode
    Samuel, Komoly
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2012, 65 (11-12): : 421 - 422
  • [48] Exercise, drug treatment, and the optimal care of multiple sclerosis patients
    Johnson, KB
    ANNALS OF NEUROLOGY, 1996, 39 (04) : 422 - 423
  • [49] Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis
    Mwema, Ariane
    Muccioli, Giulio G.
    des Rieux, Anne
    JOURNAL OF CONTROLLED RELEASE, 2023, 364 : 435 - 457
  • [50] Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil
    Cocco, Eleonora
    Fadda, Paola
    EXPERIMENTAL NEUROLOGY, 2022, 347
12345